Last reviewed · How we verify
6-methyl-prednisolone
At a glance
| Generic name | 6-methyl-prednisolone |
|---|---|
| Sponsor | Hospital Universitario Principe de Asturias |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Tazemetostat Plus CHOP in 1L T-cell Lymphoma (PHASE2)
- Comparison Of Efficacy Of Hydrocortisone And Methyl Prednisolone In Acute Severe Asthma
- Suprascapular Nerve Block With Oral Gabapentin For Pain Management In Frozen Shoulder (NA)
- Prospective Donor Specific T Response Measurment for IS Minimization in de Novo Renal Transplantation (NA)
- Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients (PHASE3)
- Immunoadsorption Versus High-dose Intravenous Corticosteroids in Relapsing Multiple Sclerosis
- Rituximab in Pretreated Elderly or Unfit B-CLL Patients (PHASE2)
- Traumatic Optic Neuropathy Treatment Trial (TONTT) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 6-methyl-prednisolone CI brief — competitive landscape report
- 6-methyl-prednisolone updates RSS · CI watch RSS
- Hospital Universitario Principe de Asturias portfolio CI